These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21898116)

  • 1. Should β blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?
    Elliott WJ; Childers WK
    Curr Cardiol Rep; 2011 Dec; 13(6):507-16. PubMed ID: 21898116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Role of Beta-Blockers in the Treatment of Hypertension.
    Cruickshank JM
    Adv Exp Med Biol; 2017; 956():149-166. PubMed ID: 27957711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atenolol as a comparator in outcome trials in hypertension: a correct choice in the past, but not for the future?
    Dahlöf B; Devereux RB; Kjeldsen SE; Lyle PA; Zhang Z; Edelman JM
    Blood Press; 2007; 16(1):6-12. PubMed ID: 17453746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beta-blockers for hypertension.
    Wiysonge CS; Bradley HA; Volmink J; Mayosi BM; Opie LH
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD002003. PubMed ID: 28107561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goals of antihypertensive therapy.
    McVeigh GE; Flack J; Grimm R
    Drugs; 1995 Feb; 49(2):161-75. PubMed ID: 7729325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke.
    Rothwell PM; Howard SC; Dolan E; O'Brien E; Dobson JE; Dahlöf B; Poulter NR; Sever PS;
    Lancet Neurol; 2010 May; 9(5):469-80. PubMed ID: 20227347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blood pressure lowering efficacy of beta-blockers as second-line therapy for primary hypertension.
    Chen JM; Heran BS; Perez MI; Wright JM
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007185. PubMed ID: 20091622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of carvedilol in hypertension: an update.
    Leonetti G; Egan CG
    Vasc Health Risk Manag; 2012; 8():307-22. PubMed ID: 22661898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers.
    Polónia J; Barbosa L; Silva JA; Bertoquini S
    Blood Press Monit; 2010 Oct; 15(5):235-9. PubMed ID: 20577082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should beta-blockers still be used as initial antihypertensive agents in uncomplicated hypertension?
    Wu A
    Ann Acad Med Singap; 2007 Nov; 36(11):962-4. PubMed ID: 18071610
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Beta blockers in hypertension treatment Will stepping back come soon?].
    Sawicki PT; Anlauf M; Haller H
    MMW Fortschr Med; 2007 Mar; 149(11):6. PubMed ID: 20104695
    [No Abstract]   [Full Text] [Related]  

  • 13. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial.
    Black HR; Elliott WJ; Grandits G; Grambsch P; Lucente T; White WB; Neaton JD; Grimm RH; Hansson L; Lacourciere Y; Muller J; Sleight P; Weber MA; Williams G; Wittes J; Zanchetti A; Anders RJ;
    JAMA; 2003 Apr 23-30; 289(16):2073-82. PubMed ID: 12709465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atenolol or metoprolol as beta-blocker in the treatment of hypertension].
    van den Born BJ; Brewster LM; Koopmans RP; van Montfrans GA
    Ned Tijdschr Geneeskd; 2005 Aug; 149(32):1808-9. PubMed ID: 16121668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of bunazosin and atenolol on glucose metabolism in obese, nondiabetic patients with primary hypertension.
    Bönner G; Schmieder R; Chrosch R; Weidinger G
    Cardiovasc Drugs Ther; 1997 Mar; 11(1):21-6. PubMed ID: 9140673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. β-blockers: a review of their pharmacological and physiological diversity in hypertension.
    Ripley TL; Saseen JJ
    Ann Pharmacother; 2014 Jun; 48(6):723-33. PubMed ID: 24687542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atenolol and cardiovascular risk: an issue close to the heart.
    Wilkinson IB; McEniery CM; Cockcroft JR
    Lancet; 2006 Feb; 367(9511):627-9. PubMed ID: 16503444
    [No Abstract]   [Full Text] [Related]  

  • 18. Beta-blockers for hypertension.
    Wiysonge CS; Bradley H; Mayosi BM; Maroney R; Mbewu A; Opie LH; Volmink J
    Cochrane Database Syst Rev; 2007 Jan; (1):CD002003. PubMed ID: 17253471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemodynamic and metabolic responses to valsartan and atenolol in obese hypertensive patients.
    Jordan J; Engeli S; Boschmann M; Weidinger G; Luft FC; Sharma AM; Kreuzberg U
    J Hypertens; 2005 Dec; 23(12):2313-8. PubMed ID: 16269974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discordant effects of beta-blockade on central aortic systolic and brachial systolic blood pressure: considerations beyond the cuff.
    Epstein BJ; Anderson S
    Pharmacotherapy; 2007 Sep; 27(9):1322-33. PubMed ID: 17723086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.